fbpx
01 / 05
1,000 Bits of Good News You May Have Missed in 2023

Blog Post | Human Development

1,000 Bits of Good News You May Have Missed in 2023

A necessary balance to the torrent of negativity.

Reading the news can leave you depressed and misinformed. It’s partisan, shallow, and, above all, hopelessly negative. As Steven Pinker from Harvard University quipped, “The news is a nonrandom sample of the worst events happening on the planet on a given day.”

So, why does Human Progress feature so many news items? And why did I compile them in this giant list? Here are a few reasons:

  • Negative headlines get more clicks. Promoting positive stories provides a necessary balance to the torrent of negativity.
  • Statistics are vital to a proper understanding of the world, but many find anecdotes more compelling.
  • Many people acknowledge humanity’s progress compared to the past but remain unreasonably pessimistic about the present—not to mention the future. Positive news can help improve their state of mind.
  • We have agency to make the world better. It is appropriate to recognize and be grateful for those who do.

Below is a nonrandom sample (n = ~1000) of positive news we collected this year, separated by topic area. Please scroll, skim, and click. Or—to be even more enlightened—read this blog post and then look through our collection of long-term trends and datasets.

Agriculture

Aquaculture

Farming robots and drones

Food abundance

Genetic modification

Indoor farming

Lab-grown produce

Pollination

Other innovations

Conservation and Biodiversity

Big cats

Birds

Turtles

Whales

Other comebacks

Forests

Reefs

Rivers and lakes

Surveillance and discovery

Rewilding and conservation

De-extinction

Culture and tolerance

Gender equality

General wellbeing

LGBT

Treatment of animals

Energy and natural Resources

Fission

Fusion

Fossil fuels

Other energy

Recycling and resource efficiency

Resource abundance

Environment and pollution

Climate change

Disaster resilience

Air pollution

Water pollution

Growth and development

Education

Economic growth

Housing and urbanization

Labor and employment

Health

Cancer

Disability and assistive technology

Dementia and Alzheimer’s

Diabetes

Heart disease and stroke

Other non-communicable diseases

HIV/AIDS

Malaria

Other communicable diseases

Maternal care

Fertility and birth control

Mental health and addiction

Weight and nutrition

Longevity and mortality 

Surgery and emergency medicine

Measurement and imaging

Health systems

Other innovations

Freedom

    Technology 

    Artificial intelligence

    Communications

    Computing

    Construction and manufacturing

    Drones

    Robotics and automation

    Autonomous vehicles

    Transportation

    Other innovations

    Science

    AI in science

    Biology

    Chemistry and materials

      Physics

      Space

      Violence

      Crime

      War

      Our World in Data | Vaccination

      Measles Vaccines Save Millions of Lives Each Year

      “Measles used to be an extremely common disease. Just sixty years ago, over 90% of children would have been infected by it, and of those who developed symptoms, around a quarter would be hospitalized.

      The United States alone had around three to four million cases annually, leading to tens of thousands of hospitalizations and hundreds of deaths each year.

      However, in 1963, John Enders developed the first effective measles vaccine. Vaccination efforts ramped up rapidly in richer countries, and in the 1970s and 1980s, they were scaled up worldwide.

      In just the last fifty years, it’s estimated that measles vaccinations have prevented over ninety million deaths worldwide. Two to three million people would die from measles every year without them.”

      From Our World in Data.

      Clinical Trials Arena | Vaccination

      Stablepharma Begins Trial of “World-First” Fridge-Free Vaccine

      “The first patient has been dosed in a Phase I trial of Stablepharma’s tetanus-diphtheria vaccine, which does not need to be refrigerated.

      The vaccine candidate, SPVX02, is completely stable at room temperature, and in testing was fully potent after three cycles of extreme temperature fluctuations ranging from -20°C to 40°C.  The candidate has been developed to withstand these temperatures through the company’s StablevaX technology.

      In what is being branded a ‘world-first’, the first patient in the trial of SPVX02 was dosed earlier this month at a National Health Service (NHS) site in the UK. The vaccine doses of SPVX02 being used in the Phase I study also have an 18-month shelf life.”

      From Clinical Trials Arena.

      Ars Technica | Vaccination

      New RSV Treatment Linked to Fall in Baby Hospitalizations

      “Far fewer babies went to the hospital struggling to breathe from RSV, a severe respiratory infection, after the debut of a new vaccine and treatment this season, according to an analysis published today by the Centers for Disease Control and Prevention…

      For the new study, CDC researchers looked at RSV hospitalization rates across two different RSV surveillance networks of hospitals and medical centers (called RSV-NET and NVSN). They compared the networks’ hospitalization rates in the 2024–2025 RSV season to their respective rates in pre-pandemic seasons between 2018 and 2020. The analysis found that among newborns (0–2 months), RSV hospitalizations fell 52 percent in RSV-NET and 45 percent in NVSN compared with the rates from the 2018–2020 period.”

      From Ars Technica.

      World Health Organization | Vaccination

      A Novel Hybrid Vaccine Delivery Approach to Combat Malaria

      “On World Malaria Day, Mali’s Ministry of Health, with support from Gavi, the Vaccine Alliance (Gavi), UNICEF and World Health Organization (WHO), launched a first-of-its-kind malaria vaccine delivery approach, aiming to reach children aged 5 to 36 months.

      The country becomes the 20th in Africa to introduce the malaria vaccine into its routine immunization programme with support from Gavi. It is the first globally to implement a hybrid approach to vaccine delivery: providing the first three doses monthly throughout the year based on age, followed by the fourth and fifth doses given seasonally in May or June of the following years, before the high malaria transmission season starts. Providing malaria vaccine doses seasonally is a strategic approach, as it aligns the period of highest vaccine protection with the period of highest malaria risk, and evidence, including research from Mali, shows it maximizes impact. 

      The R21/Matrix-M vaccine will initially be rolled out in 19 priority districts across five regions: Kayes, Koulikoro, Mopti, Ségou and Sikasso. The country currently has 927,800 R21/Matrix-M vaccines for introduction.”

      From World Health Organization.